FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282022650> ?p ?o ?g. }

• W4282022650 abstract "Objectives: To evaluate health care utilization and cost in adults with type 2 diabetes mellitus (T2DM) and peripheral artery disease (PAD) . Methods: Patients ≥ 18 years of age with T2DM, with or without PAD, were identified between January 1, 2012 and December 31, 2020 using the Optum® Clinformatics® Data Mart database. Healthcare utilization and cost was measured for the 12 months after PAD (T2DM + PAD) or random T2DM-related ICD-9/ICD-code (T2DM alone) . PAD was defined as ICD-9/ICD-code of atherosclerosis or artery thrombosis of the lower extremities from ≥ 1 hospitalization, ≥ 2 physician evaluations, or hospitalization or physician visit with relevant current procedural terminology codes. Patient cohorts were compared using an inverse probability of treatment weighting approach. Results: PAD incidence was 4.1% (n = 68,479) in the year after T2DM diagnosis. The weighted analysis compared 54,080 patients with T2DM and incident PAD (mean age, 74.0; mean Charlson comorbidity index, [CCI] 3.9) and 54,758 patients with T2DM alone (mean age, 74.2; mean CCI, 4.0) . Compared to patients with T2DM alone, patients with T2DM and PAD were more likely to have an inpatient (IP) visit (adjusted rate ratio [ARR], 2.4; 95% CI, 2.4-2.4; p &lt; 0.01) , outpatient (OP) visit (ARR, 1.5; 95% CI, 1.5-1.5; p &lt; 0.01) , or emergency room (ER) visit (ARR, 1.5; 95% CI, 1.4-1.5; p &lt; 0.01) and a longer IP stay (ARR, 2.6; 95% CI, 2.6-2.7; p &lt; 0.01) . Compared to patients with T2DM alone, patients with T2DM and PAD had higher mean healthcare costs (Total costs, $5,068 per patient per month [PPPM] vs. $2,416 PPPM; p &lt; 0.01) . In a health plan covering one million patients with T2DM, we project annual costs +$1.3B higher for patients with T2DM and PAD compared to patients with T2DM alone. Conclusions: Patients with T2DM and PAD had higher healthcare utilization and costs. Further research could investigate cost effectiveness of treatments for patients with T2DM that lower risk of PAD. Disclosure C.Uzoigwe: Employee; Novo Nordisk, Stock/Shareholder; Novo Nordisk. J.J.Rajpura: Employee; Novo Nordisk. Y.Liang: Employee; Novo Nordisk. Y.M.Paprocki: Employee; Novo Nordisk, Stock/Shareholder; Novo Nordisk. A.A.King: Advisory Panel; Novo Nordisk, Board Member; JDRF, Speaker's Bureau; Abbott, Dexcom, Inc., Lilly Diabetes, MannKind Corporation, Medtronic, Novo Nordisk." @default.
• W4282022650 created "2022-06-13" @default.
• W4282022650 creator A5002242218 @default.
• W4282022650 creator A5008390651 @default.
• W4282022650 creator A5013281261 @default.
• W4282022650 creator A5060151459 @default.
• W4282022650 creator A5090885705 @default.
• W4282022650 date "2022-06-01" @default.
• W4282022650 modified "2023-09-26" @default.
• W4282022650 title "903-P: Health Care Economic Burden and Resource Utilization in Adults with Type 2 Diabetes and Peripheral Artery Disease" @default.
• W4282022650 doi "https://doi.org/10.2337/db22-903-p" @default.
• W4282022650 hasPublicationYear "2022" @default.
• W4282022650 type Work @default.
• W4282022650 citedByCount "0" @default.
• W4282022650 crossrefType "journal-article" @default.
• W4282022650 hasAuthorship W4282022650A5002242218 @default.
• W4282022650 hasAuthorship W4282022650A5008390651 @default.
• W4282022650 hasAuthorship W4282022650A5013281261 @default.
• W4282022650 hasAuthorship W4282022650A5060151459 @default.
• W4282022650 hasAuthorship W4282022650A5090885705 @default.
• W4282022650 hasConcept C120665830 @default.
• W4282022650 hasConcept C121332964 @default.
• W4282022650 hasConcept C126322002 @default.
• W4282022650 hasConcept C134018914 @default.
• W4282022650 hasConcept C141071460 @default.
• W4282022650 hasConcept C194828623 @default.
• W4282022650 hasConcept C2779159551 @default.
• W4282022650 hasConcept C2779513377 @default.
• W4282022650 hasConcept C2908647359 @default.
• W4282022650 hasConcept C2910068830 @default.
• W4282022650 hasConcept C45827449 @default.
• W4282022650 hasConcept C555293320 @default.
• W4282022650 hasConcept C61511704 @default.
• W4282022650 hasConcept C71924100 @default.
• W4282022650 hasConcept C99454951 @default.
• W4282022650 hasConceptScore W4282022650C120665830 @default.
• W4282022650 hasConceptScore W4282022650C121332964 @default.
• W4282022650 hasConceptScore W4282022650C126322002 @default.
• W4282022650 hasConceptScore W4282022650C134018914 @default.
• W4282022650 hasConceptScore W4282022650C141071460 @default.
• W4282022650 hasConceptScore W4282022650C194828623 @default.
• W4282022650 hasConceptScore W4282022650C2779159551 @default.
• W4282022650 hasConceptScore W4282022650C2779513377 @default.
• W4282022650 hasConceptScore W4282022650C2908647359 @default.
• W4282022650 hasConceptScore W4282022650C2910068830 @default.
• W4282022650 hasConceptScore W4282022650C45827449 @default.
• W4282022650 hasConceptScore W4282022650C555293320 @default.
• W4282022650 hasConceptScore W4282022650C61511704 @default.
• W4282022650 hasConceptScore W4282022650C71924100 @default.
• W4282022650 hasConceptScore W4282022650C99454951 @default.
• W4282022650 hasIssue "Supplement_1" @default.
• W4282022650 hasLocation W42820226501 @default.
• W4282022650 hasOpenAccess W4282022650 @default.
• W4282022650 hasPrimaryLocation W42820226501 @default.
• W4282022650 hasRelatedWork W1990673946 @default.
• W4282022650 hasRelatedWork W1994497306 @default.
• W4282022650 hasRelatedWork W2028298849 @default.
• W4282022650 hasRelatedWork W2166213345 @default.
• W4282022650 hasRelatedWork W2441276067 @default.
• W4282022650 hasRelatedWork W2465063933 @default.
• W4282022650 hasRelatedWork W2510349250 @default.
• W4282022650 hasRelatedWork W2585056363 @default.
• W4282022650 hasRelatedWork W2793248551 @default.
• W4282022650 hasRelatedWork W2948447267 @default.
• W4282022650 hasVolume "71" @default.
• W4282022650 isParatext "false" @default.
• W4282022650 isRetracted "false" @default.
• W4282022650 workType "article" @default.